H.R. 9040 aims to establish fair prices for prescription drugs in the United States. The bill likely includes measures to regulate drug pricing, enhance transparency in drug costs, and possibly implement price controls or negotiate prices for certain medications to make them more affordable for consumers.
Supporters of H.R. 9040 have praised the bill for its potential to lower prescription drug costs, making medications more accessible to millions of Americans. Advocates argue that this legislation could help reduce financial burdens on families and improve overall public health outcomes by ensuring that essential medications are within reach.
Critics of H.R. 9040 have expressed concerns that the bill could lead to unintended consequences, such as reduced investment in pharmaceutical research and development. Some opponents argue that price controls may stifle innovation and result in shortages of certain drugs, ultimately harming patients who rely on new treatments.
The bill H.R. 9040 aims to establish fair prices for prescription drugs, which directly intersects with the interests of the health professionals who are the primary donors to sponsor Brad Sherman. With a staggering $120 million in contributions from the health professionals sector, there is a clear financial incentive that could influence the legislative process regarding drug pricing. This substantial amount represents a significant potential conflict of interest, as the bill's subject matter could directly impact the profitability and pricing structures within the healthcare industry.
Additionally, while other industries have engaged in lobbying activities related to this bill, the overwhelming majority of the sponsor's donations come from health professionals. This creates a scenario where the sponsor may prioritize the interests of these donors over the broader public interest in affordable healthcare. Voters should be aware that the financial ties between the sponsor and the health professionals could lead to legislation that favors industry stakeholders rather than the patients who rely on affordable prescription drugs.
These industries are both affected by this bill and among the sponsor's top donors.
| Industry | Match Type | Related Subject | Donations |
|---|---|---|---|
| Health Professionals (H01) | Sector | Health | $120,000,000 |
| Total from overlapping industries | $120,000,000 | ||
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| REFORM ACTION FUND | THE TOLMAN GROUP | $30,000 |
| VIASAT, INC. | GORMAN STRATEGY GROUP, TOO | $20,000 |
| PHOTONIS | LEWIS-BURKE ASSOCIATES, LLC | $20,000 |
| SOUTHWEST AIRLINES | THE MONDELLO GROUP LLC | $20,000 |
| HUBBARD BROADCASTING | STEPHEN WARD CONSULTING, LLC | $20,000 |
| ISTATION | THE MONDELLO GROUP LLC | undisclosed |
| LUMA ENERGY, LLC | TRUE COMPASS, LLC | undisclosed |
| SANTA FE FARMS, INC DBA ELEMENT6 DYNAMICS | STEPHEN WARD CONSULTING, LLC | undisclosed |
| LOUISIANA ENERGY SERVICES, LLC | STEPHEN WARD CONSULTING, LLC | undisclosed |
| CROSS COUNTRY HEALTHCARE, INC. | MILLER STRATEGIES, LLC | undisclosed |
| NUCOR CORPORATION | MILLER STRATEGIES, LLC | undisclosed |
| NEXUS HOSPICE OF THE HIGH DESERT LLC | MILLER STRATEGIES, LLC | undisclosed |
| TWG CADILLAC FORMULA 1 TEAM HOLDINGS, LLC | MILLER STRATEGIES, LLC | undisclosed |
| COSTAR GROUP, INC. | MILLER STRATEGIES, LLC | undisclosed |
| PADSPLIT, INC. | CONTINENTAL STRATEGY, LLC | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Brad Sherman, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
